Ultragenyx Pharmaceutical Inc.

NasdaqGS:RARE Stock Report

Market Cap: US$3.6b

Ultragenyx Pharmaceutical Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:RARE Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
06 Mar 25SellUS$72,114Howard HornIndividual1,785US$40.40
03 Mar 25SellUS$40,711Theodore HuizengaIndividual967US$42.10
03 Mar 25SellUS$635,836Erik HarrisIndividual15,103US$42.10
03 Mar 25SellUS$4,153,571Emil KakkisIndividual98,434US$42.48
03 Mar 25SellUS$607,882John PinionIndividual14,439US$42.10
03 Mar 25SellUS$376,585Eric CrombezIndividual8,945US$42.10
03 Mar 25SellUS$540,817Karah ParschauerIndividual12,846US$42.10
03 Mar 25SellUS$253,779Thomas KassbergIndividual6,028US$42.10
01 Mar 25SellUS$128,224Karah ParschauerIndividual2,990US$42.93
30 Dec 24SellUS$495,231Emil KakkisIndividual11,727US$42.23
10 Dec 24SellUS$413,650Emil KakkisIndividual8,273US$50.00
10 Oct 24SellUS$393,853Howard HornIndividual7,465US$52.76
03 Sep 24SellUS$5,113Theodore HuizengaIndividual91US$56.19
03 Sep 24SellUS$1,117,000Emil KakkisIndividual20,000US$55.85
06 Aug 24SellUS$1,003,400Emil KakkisIndividual20,000US$50.17
02 Jul 24SellUS$23,932Corazon SandersIndividual584US$40.98
12 Jun 24SellUS$441,270Karah ParschauerIndividual9,806US$45.00
10 Jun 24SellUS$71,391Corazon SandersIndividual1,737US$41.10
02 May 24SellUS$15,456Eric CrombezIndividual354US$43.66
18 Apr 24SellUS$6,262Eric CrombezIndividual142US$44.10

Insider Trading Volume

Insider Buying: RARE insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of RARE?
Owner TypeNumber of SharesOwnership Percentage
State or Government39,0510.0422%
General Public355,4520.384%
Individual Insiders3,322,6783.59%
Institutions88,783,94596%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 63.31% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.9%
The Vanguard Group, Inc.
10,034,862US$393.2m0.9%0.01%
7.07%
BlackRock, Inc.
6,536,491US$256.1m12.1%no data
4.65%
Sands Capital Management, LLC
4,298,003US$168.4m-16%0.46%
2.94%
State Street Global Advisors, Inc.
2,722,624US$106.7m2.2%no data
2.91%
Emil Kakkis
2,692,517US$105.5m1.8%no data
2.72%
T. Rowe Price Group, Inc.
2,512,423US$98.4m-18.1%0.01%
2.66%
Wellington Management Group LLP
2,457,543US$96.3m-41%0.02%
2.51%
ClearBridge Investments, LLC
2,322,205US$91.0m-4.32%0.07%
2.22%
Federated Hermes, Inc.
2,049,800US$80.3m-2.89%0.2%
2.13%
RTW Investments, LP
1,968,002US$77.1m0%1.11%
1.88%
Rock Springs Capital Management LP
1,739,813US$68.2m-12.1%2.71%
1.83%
Deutsche Asset & Wealth Management
1,693,108US$66.3m0.24%0.02%
1.81%
Invesco Ltd.
1,669,771US$65.4m1.34%0.02%
1.76%
AllianceBernstein L.P.
1,627,932US$63.8m5.28%0.02%
1.7%
Baker Bros. Advisors LP
1,576,114US$61.8m0%0.61%
1.69%
Geode Capital Management, LLC
1,562,790US$61.2m-0.53%no data
1.62%
Vestal Point Capital, LP
1,500,000US$58.8m100%3.56%
1.56%
Alyeska Investment Group, L.P.
1,439,740US$56.4m23.1%0.22%
1.52%
Alkeon Capital Management, LLC
1,405,437US$55.1m-44.2%0.39%
1.33%
Point72 Asset Management, L.P.
1,228,896US$48.1m42.6%0.11%
1.28%
Adage Capital Management, L.P.
1,183,081US$46.4m-22.5%0.08%
1.27%
Pictet Asset Management Limited
1,173,638US$46.0m125%0.03%
1.24%
Suvretta Capital Management, LLC
1,151,314US$45.1m0%1.68%
1.14%
Marshall Wace LLP
1,051,573US$41.2m27.9%0.06%
1.04%
Norges Bank Investment Management
961,794US$37.7m-4.06%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/23 00:50
End of Day Share Price 2025/03/21 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ultragenyx Pharmaceutical Inc. is covered by 35 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Huidong WangBarclays
Tazeen AhmadBofA Global Research